作者@article {Zaidat1518 = {O。o . Zaidat r . Klucznik和m·j·亚历山大·j·Chaloupka h . Lutsep和美国Barnwell m . Mawad b巷和m . j . Lynn m . Chimowitz} ={},编辑标题= {NIH注册使用的翼展支架symptomatic70 {\ textendash} 99 \ %颅内动脉狭窄},体积={70}={17},页面= {1518 - 1524}= {2008},doi = {wnl.0000306308.08229 10.1212/01.。出版商a3} = {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={背景:Warfarin-Aspirin症状性颅内疾病(WASID)试验表明,首页患者症状70 \ % 99 \ %颅内动脉狭窄的风险特别高侧中风药物治疗:18 \ % 1年(95 \ % CI = 3 \ %至24 \ %)。翼展颅内支架是另一种治疗选择,但支架的技术成功有有限的数据和结果的70 \ % 99 \ %狭窄患者治疗的翼展支架。方法:患者连续十六个医疗中心登记翼展支架在这个注册表在2005年11月和2006年10月之间。支架上的数据表明,狭窄的严重程度,技术成功(支架放置在目标病变\ < 50 \ %残余狭窄),随访造影,并收集结果。结果:共有129名患者症状70 \ % 99 \ %颅内狭窄了。技术成功率是96.7 \ %。平均前和post-stent狭窄82 \ % 20 \ %。任何频率的中风,脑内出血,30天内死亡或身体的同侧的中风超出30天是14.0 \ %在6个月(95 \ % CI = 8.7 \ % 22.1 \ %)。> = 50 \ %的频率在后续再狭窄血管造影术是13/52 (25 \ %)。 Conclusion: The use of a Wingspan stent in patients with severe intracranial stenosis is relatively safe with high rate of technical success with moderately high rate of restenosis. Comparison of the event rates in high-risk patients in Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) vs this registry do not rule out either that stenting could be associated with a substantial relative risk reduction (e.g., 50\%) or has no advantage compared with medical therapy. A randomized trial comparing stenting with medical therapy is needed. GLOSSARY: FDA = Food and Drug Administration; HDE = Humanitarian Device Exemption; ICH = intracerebral hemorrhage; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/70/17/1518}, eprint = {//www.ez-admanager.com/content/70/17/1518.full.pdf}, journal = {Neurology} }